MingSight Pharma in licensing pact with Pfizer
As per the terms of the agreement, Pfizer is expected to get upfront fee by MingSight which it will pay in the form of cash and a convertible
The US Food and Drug Administration (FDA) has granted accelerated approval to Bristol Myers Squibb’s (BMS) Zenbexus (iberdomide), along with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd), to treat adult multiple myeloma (MM) patients.
AstraZeneca and Pozen have co-developed Vimovo, which is a fixed-dose combination of enteric-coated naproxen, a pain-relieving NSAID and immediate-release esomeprazole, a proton pump inhibitor (PPI). Vimovo is indicated